GlassScriptPhysician profile
Christopher John Jones
NPI 1669407847
$3,592.07
in general payments reported to CMS, 2019-2025
26 companies · $906 in 2025
The $906 reported for 2025 was more than what 80% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $279 · 2020: $148 · 2021: $418 · 2022: $317 · 2023: $602 · 2024: $922 · 2025: $906.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,430.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,429.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $998.55 | 2021-2025 | Qelbree, Qelbree |
| Corium, LLC | $447.62 | 2021-2025 | Azstarys |
| Abbvie INC. | $329.27 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $277.78 | 2021-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $192.89 | 2025 | Hetlioz, Fanapt |
| Ironshore Pharmaceuticals INC. | $173.03 | 2019-2024 | |
| Neos Therapeutics, LP | $125.63 | 2021-2024 | Adzenys Xr-Odt |
| Collegium Pharmaceutical, INC. | $118.79 | 2025 | Jornay Pm |
| Sunovion Pharmaceuticals INC. | $116.08 | 2019-2022 | |
| Adlon Therapeutics L.P. | $107.27 | 2019-2021 | |
| Tris Pharma INC | $93.10 | 2019-2025 | Dyanavel Xr |
| Janssen Pharmaceuticals, INC | $90.22 | 2019-2024 | Spravato |
| Almatica Pharma LLC | $77.74 | 2023-2025 | Loreev Xr, Sertraline Hcl |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $68.93 | 2025 | Caplyta |
| Noven Therapeutics, LLC | $64.31 | 2024 | Xelstrym |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $53.77 | 2024-2025 | Cobenfy |
| Allergan, INC. | $49.99 | 2019-2020 | |
| Alkermes, INC. | $41.01 | 2024 | Aristada, Lybalvi |
| Vertical Pharmaceuticals, LLC | $31.85 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $28.61 | 2024 | Rexulti |
| Idorsia Pharmaceuticals US INC | $23.32 | 2025 | Quviviq |
| Bausch Health US, LLC | $22.06 | 2022 | |
| Axsome Therapeutics, INC. | $16.84 | 2024 | Auvelity |
| Arbor Pharmaceuticals, INC. | $15.05 | 2019 | |
| Lundbeck LLC | $14.54 | 2019 | |
| Shire North American Group INC | $13.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.